The MUC1-C oncoprotein as a target in hematologic malignancies.

作者信息

Schlom Jeffrey

机构信息

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

出版信息

Cancer Biol Ther. 2010 Sep 1;10(5):492-4. doi: 10.4161/cbt.10.5.13150. Epub 2010 Sep 26.

DOI:10.4161/cbt.10.5.13150

PMID:20716962

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3230282/

Abstract

摘要

相似文献

The MUC1-C oncoprotein as a target in hematologic malignancies.

Cancer Biol Ther. 2010 Sep 1;10(5):492-4. doi: 10.4161/cbt.10.5.13150. Epub 2010 Sep 26.

Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein.

Cancer Biol Ther. 2010 Sep 1;10(5):483-91. doi: 10.4161/cbt.10.5.12584. Epub 2010 Sep 4.

MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells.

Cancer Res. 2007 Dec 15;67(24):11576-84. doi: 10.1158/0008-5472.CAN-07-2756.

MUC1 in hematological malignancies.

Leuk Lymphoma. 2016 Nov;57(11):2489-98. doi: 10.1080/10428194.2016.1195500. Epub 2016 Jun 27.

Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells.

Chem Biol Interact. 2015 Dec 5;242:195-201. doi: 10.1016/j.cbi.2015.10.004. Epub 2015 Oct 9.

Proteomic-based identification of Apg-2 as a therapeutic target for chronic myeloid leukemia.

Cell Signal. 2013 Dec;25(12):2604-12. doi: 10.1016/j.cellsig.2013.08.023. Epub 2013 Sep 3.

BCR/ABL oncoprotein-targeted antitumor activity of antisense oligodeoxynucleotides complementary to bcr/abl mRNA and herbimycin A, an antagonist of protein tyrosine kinase: inhibitory effects on in vitro growth of Ph1-positive leukemia cells and BCR/ABL oncoprotein-associated transformed cells.

Leuk Lymphoma. 1993 Jul;10(4-5):307-16. doi: 10.3109/10428199309148553.

hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis.

Mol Cell Biol. 2002 Apr;22(7):2255-66. doi: 10.1128/MCB.22.7.2255-2266.2002.

Inhibition of USP1, a new partner of Bcr-Abl, results in decrease of Bcr-Abl level in K562 cells.

Exp Oncol. 2020 Jun;42(2):109-114. doi: 10.32471/exp-oncology.2312-8852.vol-42-no-2.14533.

Advances in the treatment of haematological malignancies: optimal sequence of CML treatment.

Ann Oncol. 2007 Jul;18 Suppl 9:ix58-63. doi: 10.1093/annonc/mdm295.

引用本文的文献

Cutaneous T-Cell Lymphoma: Yin-Yang Effects of Transcription Factors HLF and NFIL3 in Regulation of Malignant T-Cell Markers in the Context of HDAC Inhibitor Romidepsin Treatment.

Cancers (Basel). 2025 Jul 17;17(14):2380. doi: 10.3390/cancers17142380.

MUC1 in hematological malignancies.

Leuk Lymphoma. 2016 Nov;57(11):2489-98. doi: 10.1080/10428194.2016.1195500. Epub 2016 Jun 27.

本文引用的文献

Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein.

Cancer Biol Ther. 2010 Sep 1;10(5):483-91. doi: 10.4161/cbt.10.5.12584. Epub 2010 Sep 4.

Mucins in cancer: function, prognosis and therapy.

Nat Rev Cancer. 2009 Dec;9(12):874-85. doi: 10.1038/nrc2761.

Functional targeting of the MUC1 oncogene in human cancers.

Cancer Biol Ther. 2009 Jul;8(13):1197-203. doi: 10.4161/cbt.8.13.8844. Epub 2009 Jul 27.

Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells.

Cancer Res. 2009 Jun 15;69(12):5133-41. doi: 10.1158/0008-5472.CAN-09-0854. Epub 2009 Jun 2.

Intracellular MUC1 peptides inhibit cancer progression.

Clin Cancer Res. 2009 Jan 1;15(1):100-9. doi: 10.1158/1078-0432.CCR-08-1745.

Translation of the Philadelphia chromosome into therapy for CML.

Blood. 2008 Dec 15;112(13):4808-17. doi: 10.1182/blood-2008-07-077958.

Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy.

Crit Rev Immunol. 2007;27(5):451-62. doi: 10.1615/critrevimmunol.v27.i5.40.

MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells.

Cancer Res. 2007 Dec 15;67(24):11576-84. doi: 10.1158/0008-5472.CAN-07-2756.

Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62.

J Biol Chem. 2007 Jul 6;282(27):19321-30. doi: 10.1074/jbc.M703222200. Epub 2007 May 11.

MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin.

Cancer Res. 2005 Nov 15;65(22):10413-22. doi: 10.1158/0008-5472.CAN-05-2474.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验